You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

OPILL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Opill patents expire, and when can generic versions of Opill launch?

Opill is a drug marketed by Laboratoire Hra and is included in one NDA.

The generic ingredient in OPILL is norgestrel. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the norgestrel profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OPILL?
  • What are the global sales for OPILL?
  • What is Average Wholesale Price for OPILL?
Summary for OPILL
Drug patent expirations by year for OPILL
Drug Prices for OPILL

See drug prices for OPILL

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OPILL
Generic Entry Date for OPILL*:
Constraining patent/regulatory exclusivity:
RX TO OTC SWITCH OR OTC USE
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for OPILL

OPILL is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OPILL is ⤷  Sign Up.

This potential generic entry date is based on RX TO OTC SWITCH OR OTC USE.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting OPILL

RX TO OTC SWITCH OR OTC USE
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Laboratoire Hra OPILL norgestrel TABLET;ORAL 017031-001 Approved Prior to Jan 1, 1982 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OPILL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Laboratoire Hra OPILL norgestrel TABLET;ORAL 017031-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Laboratoire Hra OPILL norgestrel TABLET;ORAL 017031-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Laboratoire Hra OPILL norgestrel TABLET;ORAL 017031-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for OPILL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1453521 C201630040 Spain ⤷  Sign Up PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211
1453521 122015000093 Germany ⤷  Sign Up PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1453521 39/2015 Austria ⤷  Sign Up PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521 300814 Netherlands ⤷  Sign Up PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.